alcian-blue and Neoplasms

alcian-blue has been researched along with Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for alcian-blue and Neoplasms

ArticleYear
Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin.
    The American journal of pathology, 1992, Volume: 140, Issue:3

    Platelet-derived growth factor (PDGF) is known to stimulate the proliferation of connective tissue-derived cells in vitro. Less is known about its functions in vivo, and the role of PDGF in the development of human tumors has not been clarified. The authors have investigated the occurrence of PDGF and PDGF receptors in a series of proliferative disorders of fibroblastic origin using immunohistochemical and in situ hybridization techniques. High expression of PDGF beta-receptor mRNA and protein was found in the malignant tumors, and also in some benign lesions, such as dermatofibroma. In all these cases, benign as well as malignant, the PDGF B-chain mRNA, and less clearly, the PDGF A-chain mRNA, were coexpressed with the beta-receptor. In contrast, high expression of PDGF alpha-receptor mRNA was only found in fully malignant lesions, i.e., malignant fibrous histiocytoma. These data indicate that an autocrine growth stimulation via the PDGF beta-receptor could occur in an early phase of tumorigenesis, and may be a necessary but insufficient event for the progression into fully malignant human connective tissue lesions.

    Topics: Alcian Blue; Antibody Specificity; Fibroblasts; Humans; Immunohistochemistry; Neoplasms; Nucleic Acid Hybridization; Platelet-Derived Growth Factor; Receptors, Cell Surface; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Skin Diseases; Staining and Labeling

1992
Value of immunocytochemistry in the study of malignant effusions.
    Diagnostic cytopathology, 1987, Volume: 3, Issue:3

    Recognition of malignant effusion relies heavily on cytologic examination despite the difficulty of distinguishing atypical mesothelial hyperplasia from metastatic carcinoma. The combination of CEA, EMA, vimentin, keratin, high-molecular-weight cytokeratin (HMWK), low-molecular-weight cytokeratin (LMWK), and Alcian blue was tested in 51 cytologic specimens of pleural, peritoneal, and pericardial effusions. These showed metastatic carcinoma in 38 cases (ovary, 14; lung, 8; breast, 7; GI, 4; endometrium, 4; bladder, 1) and mesothelial processes in 13 (hyperplasia, 9; mesothelioma, 4). Strong positivity for EMA (92%), CEA (90%), and Alcian blue (71%) was noted in metastatic carcinoma but not in the mesothelial processes. Keratin was positive in all cases of mesothelioma but occurred also in mesothelial hyperplasias (44%) and metastatic carcinomas (47%). In mesothelial cells, HMWK was consistently stronger than LMWK, whereas in adenocarcinoma the reverse was true. There was no difference in the degree or distribution of positivity of any of the markers among the various primary sites of the neoplasms. Our findings are consistent with the view that immunocytochemistry with a battery of antibodies is useful in the recognition of malignant effusions but cannot, as yet, determine the site of origin of metastatic neoplasms.

    Topics: Alcian Blue; Ascitic Fluid; Carcinoembryonic Antigen; Humans; Immunoenzyme Techniques; Intermediate Filament Proteins; Membrane Glycoproteins; Mucin-1; Neoplasms; Pericardial Effusion; Pleural Effusion

1987
[Histochemical study with alcian blue on some malignant tumors of the facial bones].
    L'Oto-rino-laringologia italiana, 1959, Volume: 28

    Topics: Alcian Blue; Coloring Agents; Facial Bones; Facial Neoplasms; Glycosaminoglycans; Humans; Neoplasms; Staining and Labeling

1959